Entries |
Document | Title | Date |
20080214518 | Pharmaceutical Composition Comprising an Anti-Bacterial Agent and an Active Ingredient Selected From Carveol, Thymol, Eugenol, Borneol and Carvacrol - The invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is an antibiotic. | 09-04-2008 |
20090088415 | Controlled release pharmaceutical compositions - A non-disintegrating, non-eroding, non-bioadhesive and non-swelling oral controlled release pharmaceutical composition and process for preparation of such compositions is provided which comprises at least one high dose water soluble active ingredient, at least one diluent, at least one binder, and a polymer system comprising of at least one release controlling polymer wherein the composition formulated into a suitable dosage form maintains its geometric shape even after the drug has diffused from the dosage form and provides the concentrations of active ingredient above effective levels for extended periods of time, optionally with other pharmaceutically acceptable excipients. The compositions preferably comprise antibiotic(s) as active ingredient, more preferably Amoxicillin or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof, most preferably amoxicillin sodium, either alone or in combination with other antibiotic(s). Also described are controlled release compositions which provide an initial burst release of approximately 20%-40% of the active ingredient within one hour for achieving blood levels equivalent to minimum inhibitory concentration, while maintaining these levels for an extended period of time. | 04-02-2009 |
20090186865 | Lyophilization Process - An improved process for the production of lyophilized Piperacillin alone or in combination with Tazobactam with improved pH adjustment, by degassing the solution of products to a controlled low carbon dioxide content prior to lyophilization. | 07-23-2009 |
20100099656 | Neurotherapeutic compositions - Novel neuroprotectant compositions and methods are described. (β-Lactamase inhibitors are used to prevent or reduce loss of neuronal cells and neuronal cell function in patients afflicted with or susceptible to disease states or conditions known to result in or cause neuronal tissue insult. | 04-22-2010 |
20100160277 | COMPOSITIONS FOR COMBATING BETA-LACTAMASE-MEDICATED ANTIBIOTIC RESISTANCE USING BETA-LACTAMASE INHIBITORS USEFUL FOR INJECTION - The invention describes a composition for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitor useful for injection, capable of pharmaceutical application. The invention relates to pharmaceutical composition containing ceftriaxone (normally as ceftriaxone sodium) and sulbactam (normally as sulbactam sodium). Such compositions are found to be useful for intramuscular or intravenous administration as antibiotics for hospitalized patients with serious infections. Specifically, this invention relates to a pharmaceutical composition further including an aminocarboxylic acid chelating agent, for example, ethylenediaminetetraacetic acid (EDTA), or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions of this invention have been found normally to enhance resistance to particulate formation in solutions to be administered parenterally. The invention also gives details of the dosage forms stored in sealed containers to be reconstituted before use. The invention also gives a process to manufacture these compositions. The invention gives a method of treating a subject having a condition or disorder, wherein a treatment with ceftriaxone sodium and sulbactam sodium is indicated. | 06-24-2010 |
20100197649 | Compositions and Methods for Diagnosing and Treating Community-Acquired Methicillin-Resistant Staphylococcus Aureus - The present invention includes compositions and methods for diagnosing and treating CA-MRSA infections in patients. The methods are based on the finding that combining cefoxitin and a synthetic penicillin in a treatment regimen results in a synergistic effect of the two drugs, an effect that is related to PBP4 activity in CA-MRSA isolates. Also provided is a CA-MRSA-specific biomarker which can be used to detect the presence of a CA-MRSA infection in a patient. | 08-05-2010 |
20110172200 | USE OF INHIBITOR OF BETA-LACTAMASES AND ITS COMBINATION WITH BETA-LACTAM ANTIBIOTICS - The present invention relates to a pharmaceutical composition with broad-spectrum of activity against class A, class C and D enzymes comprising an antibiotic and a pharmaceutically effective amount of a compound of Formula (I), compounds of Formula (I), the use of a therapeutically effective amount of one or more compounds of Formula (I) as a broad-spectrum beta-lactamase inhibitor and the use of such a pharmaceutical composition for the treatment of an infection in humans or animals caused by bacteria. | 07-14-2011 |
20110190252 | COMPOSITIONS INCLUDING CLAVULANIC ACID AND RELATED METHODS OF USE - Methods of treating a disorder in a subject comprising administering to a subject an elastase inhibitor such as clavulanic acid, sulbactam, or tazobactam are described. | 08-04-2011 |
20120129826 | Method of Treating Depression - Methods for treatment of depression-related mood disorders in mammals, particularly humans are disclosed. The methods of the invention include administration of compounds capable of enhancing glutamate transporter activity in the brain of mammals suffering from depression. ATP-sensitive K | 05-24-2012 |
20120190663 | USE OF FREE DNA AS AN EARLY PREDICTOR OF SEVERITY IN ACUTE PANCREATITIS - This invention provides methods of determining the risk of AP development in an individual, as well as the diagnosis, prognosis, and treatment of acute pancreatitis (AP) in an individual, by determining the presence or absence of significantly high levels of free serum DNA in the subject relative to levels in a healthy individual. In other embodiments, the invention further provides methods of determining the risk of severe AP development, prognosis, diagnosis, and treatment of a severe form of acute pancreatitis based upon the presence of significantly high levels of free serum DNA in the subject relative to an individual who has and maintains a mild form of acute pancreatitis. | 07-26-2012 |
20120232047 | SUBSTITUTED CLAVULANIC ACID - The present invention relates to compounds of formula I | 09-13-2012 |
20130237512 | STABILIZING COMPOSITIONS FOR ANTIBIOTICS AND METHODS OF USE - The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v). | 09-12-2013 |
20140088067 | TAZOBACTAM ARGININE COMPOSITIONS - This disclosure provides compositions containing solid forms of tazobactam arginine, and methods of manufacturing and using these compositions. | 03-27-2014 |
20140088068 | 1,6-Diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections - Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed. | 03-27-2014 |
20140162995 | Compositions Comprising Antibacterial Agent and Tazobactam - A pharmaceutical composition comprising antibacterial agent and tazobactam, wherein the ratio of tazobactam to the antibacterial agent in the composition is in the range of from about 0.5 to about 2 gram of tazobactam per gram of the antibacterial agent, are disclosed. | 06-12-2014 |
20140179659 | METHOD FOR SUPPRESSING SURGICAL SITE INFECTION AND COLUMN TO BE USED FOR THE METHOD - An object of the present invention is to provide a method for suppressing surgical site infections (SSI) that have occurred at extremely high incidence rates at the time of surgical operations and particularly surgical operations on digestive system organs, and to provide a column to be used for the method. According to the present invention, a method is provided for suppressing surgical site infections, which comprises the steps of: (a) administering a chemotherapeutic drug for treating and/or preventing a surgical site infection; and (b) collecting blood from a surgical subject and removing leukocytes that comprise neutrophils from the blood during or within 24 hours after surgical operation, and then returning the blood from which the leukocytes have been removed to the surgical subject. The present invention also provides a column for blood circulation which is filled with a carrier having affinity for leukocytes comprising neutrophils, which is used for suppressing a surgical site infection during or within 24 hours after surgical operation on a digestive system organ. | 06-26-2014 |
20140187528 | TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS - This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions. | 07-03-2014 |
20140206659 | TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS - This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions. | 07-24-2014 |
20140213566 | Pharmaceutical Compositions Comprising Beta-Lactam Antibiotic, Sulbactam and Beta-Lactamase Inhibitor - Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) at least one beta-lactam antibiotic or a pharmaceutically acceptable salt thereof, (b) sulbactam or a pharmaceutically acceptable salt thereof, and (c) at least one beta-lactamase inhibitor or a pharmaceutically acceptable salt thereof, with the provision that the beta-lactamase inhibitor is not sulbactam. | 07-31-2014 |
20140213567 | TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS - This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions. | 07-31-2014 |
20140221330 | NDM INHIBITOR - An objective of the present invention is to provide a novel NDM (New Delhi metallo-β-lactamase) inhibitor that functions as a drug for restoring the antibacterial activity of β-lactam antibiotics that have been inactivated as a result of decomposition by NDM. According to the present invention, there is provided an NDM inhibitor contains a compound represented by general formula (I): | 08-07-2014 |
20140243302 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS - Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions. | 08-28-2014 |
20140274989 | MANUFACTURING BETA-LACTAM COMBINATION PRODUCTS - This disclosure relates to the manufacture of pharmaceutical compositions comprising an antibiotic compound and a beta-lactamase inhibitor compound when both compounds have a chemical structure that includes a beta-lactam ring, as well as resulting pharmaceutical compositions. | 09-18-2014 |
20140274990 | CEFTOLOZANE PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions can include an amount of sodium chloride effective to stabilize ceftolozane in a lyophilized formulation. | 09-18-2014 |
20140274991 | CEFTOLOZANE PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions can include ceftolozane and an amount of sodium chloride effective to provide improved ceftolozane stability. | 09-18-2014 |
20140274992 | CEFTOLOZANE PHARMACEUTICAL COMPOSITIONS - Pharmaceutical formulations can include ceftolozane and an alkalizing agent such as L-arginine. | 09-18-2014 |
20140274993 | CEFTOLOZANE-TAZOBACTAM PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions can include ceftolozane lyophilized in the absence of tazobactam. | 09-18-2014 |
20140274994 | STABILIZING CEFTOLOZANE - Pharmaceutical compositions can include an amount of a ceftolozane and a stabilizing agent in a formulation for parenteral administration. | 09-18-2014 |
20140274995 | PARENTERAL CEFTOLOZANE ANTIBIOTIC COMPOSITIONS - Parenteral pharmaceutical compositions including ceftolozane and tazobactam can be formulated to provide desired levels of osmolality, pH and ceftolozane stability. | 09-18-2014 |
20140274996 | TAZOBACTAM AND CEFTOLOZANE ANTIBIOTIC COMPOSITIONS - This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of making those compositions, and related methods and uses of these compositions. | 09-18-2014 |
20140274997 | CEPHALOSPORIN PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions including a cephalosporin disclosed herein as having the structure of formula (III). | 09-18-2014 |
20140274998 | CEFTOLOZANE-TAZOBACTAM PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions can include ceftolozane lyophilized in the absence of tazobactam. | 09-18-2014 |
20140303136 | CEFTOLOZANE ANTIBIOTIC COMPOSITIONS - This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions. | 10-09-2014 |
20140309205 | CEFTOLOZANE ANTIBIOTIC COMPOSITIONS - This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions. | 10-16-2014 |
20140329793 | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The invention features pharmaceutical compositions including (i) a drug, and (ii) a PEG fatty acid ester or PPG fatty acid ester in an amount sufficient to increase the oral bioavailability of the drug. | 11-06-2014 |
20140371194 | METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS - This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis. | 12-18-2014 |
20150031658 | ETHOXYPHENYL THIENYL COMPOUNDS AND METHODS FOR THE TREATMENT OFBACTERIAL INFECTIONS - This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis. | 01-29-2015 |
20150045336 | TAZOBACTAM AND CEFTOLOZANE ANTIBIOTIC COMPOSITIONS - This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of making those compositions, and related methods and uses of these compositions. | 02-12-2015 |
20150072968 | Treating Infections with Ceftolozane/Tazobactam in Subjects Having Impaired Renal Function - Disclosed is a method of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra-abdominal infection or a complicated urinary tract infection. | 03-12-2015 |
20150080360 | METHODS FOR TREATING INTRAPULMONARY INFECTIONS - This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane. | 03-19-2015 |
20150094293 | SOLID FORMS OF CEFTOLOZANE - Novel solid forms of ceftolozane are described, as well as methods for the preparation and use of these solid forms. | 04-02-2015 |
20150306076 | TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS - This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions. | 10-29-2015 |
20150328201 | NITROGEN CONTAINING COMPOUNDS - Compounds of Formula (I), their preparation and use in preventing or treating bacterial infection is disclosed. | 11-19-2015 |
20160000921 | CEFTOLOZANE ANTIBIOTIC COMPOSITIONS - This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions. | 01-07-2016 |
20160113910 | Treating Infections with Ceftolozane/Tazobactam in Subjects Having Impaired Renal Function - Disclosed are methods of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra-abdominal infection or a complicated urinary tract infection. | 04-28-2016 |
20190144432 | METALLO-BETA-LACTAMASE INHIBITORS | 05-16-2019 |